Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.65 +0.52 (+2.07%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial.  On Monday, Moderna (NASDAQ: MRNA) and Merck & Co... 
Via Benzinga
The Income Investor’s Dream Team: 7 Sturdy Dividend Stocks Yielding 6%
Dividend stocks yielding 6% are at the higher end of risk but these shares won't fail income investors anytime soon. 
Via InvestorPlace
7 High-Yield Dividend Stocks That Work While You Sleep
Although it’s easy to focus only on compelling growth plays, investors should also branch out to high-yield dividend stocks. 
Via InvestorPlace
1 Beaten-Down S&P 500 Dividend Stock to Buy in June and Hold For a Decade or Longer
Pfizer's list of patent-protected medicines is growing by leaps and bounds, but its stock price is under pressure. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Pfizer Unusual Options Activity For June 03
Via Benzinga
Pfizer's Options Frenzy: What You Need to Know
Via Benzinga
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments 
Via MarketBeat
2 No-Brainer Dividend Stocks You Can Buy With $100 in June
This pair of high-yield dividend payers offer yields near 6% and a chance for steady payout raises in the years to come. 
Via The Motley Fool
Is Moderna Stock a Buy Now That It's a 2-Product Company?
The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response. 
Via The Motley Fool
7 Overlooked Stocks That Belong in Every Portfolio
Looking beyond the headlines creates an opportunity for investors who have the patience to seek must-own overlooked stocks. 
Via InvestorPlace
Moderna Investors Just Got Some Bullish News
This news could be worth billions... 
Via The Motley Fool
3 Discounted Stocks Poised for a Major Upswing
Explore discounted upswing stocks with strong financials and strategic advantages heading for a rebound soon. 
Via InvestorPlace
Blue-Chip Blunders: 7 Stocks to Sell as Management Missteps Mount
Sometimes top companies make bottom-shelf decisions; such is the case with these seven blue-chip stocks to sell. 
Via InvestorPlace
3 Stocks to Buy for Huge Income
All 3 of these stocks have a yield above 5%. 
Via The Motley Fool
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
From Takeda Pharmaceutical Company Limited
Via Business Wire
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
From Pfizer Inc.
Via Business Wire
Is Pfizer the Best Dividend Stock for You?
Short-term expectation worries have elevated Pfizer's dividend yield. 
Via The Motley Fool
Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer
Pfizer's Phase 3 CROWN trial results show Lorbrena significantly outperforms Xalkori in treating ALK-positive advanced NSCLC. 
Via Benzinga
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
Moderna's RSV vaccine will launch a year behind Pfizer and GSK, but it could become the market leader over the next five years. 
Via Investor's Business Daily
Exposures Product Safety
How To Earn $500 A Month From Pfizer Stock
New York-based Pfizer currently has a dividend yield of 5.96% — a quarterly dividend of 42 cents a share ($1.68 a year). 
Via Benzinga
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
From Pfizer Inc.
Via Business Wire
Ginkgo Bioworks Stock: Bull vs. Bear
This innovative biotechnology company hopes to turn things around. 
Via The Motley Fool
Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?
Pfizer's dividend yield is rising as the stock price is falling. 
Via The Motley Fool
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
Via AB Newswire
Exposures COVID-19
Moderna Pops After Confirming The U.S. Government Could Back Its Bird Flu Vaccine
The company expects to have data soon from its Phase 1 and Phase 2 study of a bird flu vaccine. 
Via Investor's Business Daily
Beat the Dow Jones With This Cash-Gushing Dividend Stock
With one decade of doubling the Dow Jones' total return under its belt, Zoetis looks ready to deliver another 10 years of outperformance. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Steady Gains, Solid Yields: 7 Low-Beta Stocks Paying 5%+ Dividends
These are the low-beta dividend stocks to buy, as they represent companies with strong fundamentals and robust cash flow visibility. 
Via InvestorPlace
3 Dividend Stocks to Double Up on Right Now
The stories for these great dividend stocks are better than many might think. 
Via The Motley Fool
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.